Sohini Das

All stories by Sohini Das

Biocon Biologics Plan Molecule Launch Every 1-2 Years

Biocon Biologics Plan Molecule Launch Every 1-2 Years

Rediff.com2 days ago

'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.'

How start-ups are shaking up offline pharma business

How start-ups are shaking up offline pharma business

Rediff.com3 Aug 2022

Bulk of the medicine sales in the $22-24 billion domestic pharma market happens through offline retail chemists. With the entry of online pharmacies, this space has started to witness a shake-up. Sample this: Dawaa Dost, a Rajasthan based digital health start-up, generates medicine orders from 'kirana' stores and women self-help groups (SHGs) that operate in villages, and then service these orders through its affiliated network of pharmacies. Biddano, another health-tech start-up, has a platform that acts as an aggregator for neighbourhood chemist shops.

India's rising medical devices imports hurt small and medium units

India's rising medical devices imports hurt small and medium units

Rediff.com19 Jul 2022

India's medical devices imports surged 41 per cent to touch Rs 63,200 crore in 2021-22, led by a 48 per cent year-on-year (YoY) jump in imports from China to Rs 13,538 crore, the commerce ministry data analysed by the Association of Indian Medical Device Industry (AiMeD) has showed. Local industry players say this has led to several small and medium units to shut shop. Rakesh Vaid of Usha Fabs, a garments exporter, had started making N95 masks in his Gurgaon factory during the peak of the Covid-19 pandemic.

For the first time, Centre allows a private player to process opium

For the first time, Centre allows a private player to process opium

Rediff.com14 Jul 2022

The central government has for the first time allowed a private company, Bajaj Healthcare, to process opium to extract alkaloids used to make pain-killers, cough syrups, and even cancer drugs. Two government factories in Ghazipur, Uttar Pradesh, and Neemuch, Madhya Pradesh, do the work yet, processing some 800 tonnes of opium gum annually to extract alkaloids. The government on Tuesday gave Thane-based Bajaj Healthcare an initial contract to process 500 tonnes of opium gum annually and wants production to be at 800 tonnes per annum (tpa) in the next five years, indicating the state's exit from the highly-regulated sector.

Millions of Covid vaccine doses are set to expire in India

Millions of Covid vaccine doses are set to expire in India

Rediff.com20 Jun 2022

Pune-based Serum Institute of India (SII) is sitting on 200 million doses of Covishield that were manufactured in December and are set to expire in September. The company is likely to destroy these vaccines if nothing works out, Sohini Das reports.

'We can't get rid of COVID-19 for a long time to come'

'We can't get rid of COVID-19 for a long time to come'

Rediff.com10 Jun 2022

'There will be ups and downs, and we have to plan how we live with it now.'

SIIto test Novavax's Omicron-specific vaccine

SIIto test Novavax's Omicron-specific vaccine

Rediff.com6 Jun 2022

The Drugs Controller General of India has approved the manufacture of this Sars-CoV-2 spike protein recombinant nano-particle vaccine for 'examination, test, and analysis', reports Sohini Das.

Smaller towns witness strong growth in sales of medicines

Smaller towns witness strong growth in sales of medicines

Rediff.com27 May 2022

Medicine sales grew at a fast clip in smaller cities like Madurai, Meerut, Agra, and Varanasi in the last 12 months. The domestic pharmaceutical market, overall, has grown 12.3 per cent in this period, according to data from IQVIA MAT for April. MAT refers to the moving annual turnover or the turnover of the last 12 months. The data further showed that the top 30 cities contributed around 32 per cent to sales.

20-30% new products may be open to USFDA inspection

20-30% new products may be open to USFDA inspection

Rediff.com23 May 2022

With all major US export-oriented drug manufacturing plants in the country up for inspection in 2022, some estimates peg that at least 20-30 per cent of the new product launches lined up for the US will be subject to on-site inspection by the US Food and Drug Administration (USFDA). The last two years saw limited physical inspections due to travel restrictions during the pandemic. "Pre-Covid, the frequency and number of inspections of manufacturing plants in India by USFDA had increased significantly," analysts from ICICI Securities Research noted. "With growing ANDA filings, especially for complex products. "We expect this trend to return with the environment normalising," analysts from ICICI Securities Research noted.

Indian pharma cos get a shot in the arm in $12-bn Australian drug market

Indian pharma cos get a shot in the arm in $12-bn Australian drug market

Rediff.com29 Apr 2022

Indian drug firms get a shot in the arm in the $12 bn Australian drug market as the Therapeutic Goods Administration (TGA), Australia agrees to accelerate the drug approval process in that country for Indian players who already have an approved plant and product from one of the stringent regulatory authorities like US, EU or Canada. From current sales of $340 mn, the Indian firms can see a significant upside in sales; felt Dinesh Dua, former chairman of the Pharmaceutical Exports Promotion Council of India (Pharmexcil), and the MD of Nectar Lifesciences. He highlighted that only 12 percent of the Australian drug market is generic, as against 80-90 per cent in the US or EU. Of this $1.5 bn generic drug market in India, Indian companies have a small share.

Why WHO suspended supply of Covaxin through UN agencies

Why WHO suspended supply of Covaxin through UN agencies

Rediff.com4 Apr 2022

Sources close to the development said the company had no further supply commitments to the WHO, and therefore, there was no suspension of any upcoming orders, reports Sohini Das.

Serum, Bharat Biotech halt Covid vaccine production as demand slips

Serum, Bharat Biotech halt Covid vaccine production as demand slips

Rediff.com4 Apr 2022

Sources indicated that there were no fresh orders from the Government of India, and their supply commitments have ended as of March 31, reports Sohini Das.

Hospital chain plans to put expectant parents on cloud nine

Hospital chain plans to put expectant parents on cloud nine

Rediff.com1 Apr 2022

No expecting mother ever needs to travel for more than 30 minutes to reach one of their hospitals, believes the Cloudnine group.

India's pharma cos hit by 'China-made disruptions'

India's pharma cos hit by 'China-made disruptions'

Rediff.com31 Mar 2022

With intermittent disruptions in the supply chain of raw materials from China, the Indian pharma industry has braced itself with bigger inventory. Even smaller drug makers are now carrying a month of buffer stock of key raw materials, said industry insiders. The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players. Shipments are critical for the Indian drug industry, which imports 70 per cent of its raw material from China.

'We have to ensure vaccines work against new variants'

'We have to ensure vaccines work against new variants'

Rediff.com11 Jan 2022

Adar Poonawalla says it took a five-minute chat with his father Cyrus before making the decision to manufacture Covishield. The bet paid off, and handsomely. Serum Institute now has the capacity to make 4 billion doses of Covishield annually.

Covaxin shelf life extended, Bharat Biotech relabels old stocks

Covaxin shelf life extended, Bharat Biotech relabels old stocks

Rediff.com5 Jan 2022

The company had in December said that the CDSCO had approved a 12-month shelf life for Covaxin, which was nine months earlier, Sohini Das reports.

Does India have enough jabs to expand vaccination drive?

Does India have enough jabs to expand vaccination drive?

Rediff.com3 Jan 2022

A back of the envelope calculation shows that India has roughly over 680 million doses of Covid-19 vaccines consisting primarily of Covishield doses.

Covishield accounts for 88% of Covid jabs in India

Covishield accounts for 88% of Covid jabs in India

Rediff.com1 Jan 2022

Serum Institute has the capacity to make 250 million doses of Covishield monthly.

Are You Eligible For A Booster Shot?

Are You Eligible For A Booster Shot?

Rediff.com27 Dec 2021

'Someone may have diabetes, but at what level the disease qualifies as a comorbid condition is something a doctor will decide upon and certify accordingly.'

Covishield booster works against Omicron

Covishield booster works against Omicron

Rediff.com24 Dec 2021

If the vaccine is recommended for use as a booster against Omicron, it may significantly boost the demand for Covishield in India.

Next